Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | YAP1 | P46937 | 3/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8266224 | 0.91 | TACR1 (0.49) | TACR1YAP1JAK2JAK1PRMT5 | |
| SCHEMBL10183269 | 0.91 | TACR1 (0.49) | TACR1YAP1JAK2JAK1PRMT5 | |
| SCHEMBL12054719 | 0.91 | TACR1 (0.49) | TACR1YAP1JAK2JAK1PRMT5 | |
| SCHEMBL2238462 | 0.90 | TACR1 (0.51) | TACR1YAP1JAK2JAK1PRMT5 | |
| SCHEMBL10182038 | 0.89 | TACR1 (0.50) | TACR1JAK2JAK1PDE4BUSP30 | |
| SCHEMBL10183376 | 0.88 | TACR1 (0.50) | TACR1YAP1JAK2JAK1PRMT5 | |
| SCHEMBL1752278 | 0.87 | PDE4B (0.53) | TACR1PDE4BUSP30GPR119STS | |
| SCHEMBL12592451 | 0.87 | PDE4B (0.53) | TACR1PDE4BUSP30GPR119STS | |
| SCHEMBL11306145 | 0.85 | YAP1 (0.55) | YAP1PRMT5KCNH2GPR119STS | |
| SCHEMBL8265507 | 0.85 | TACR1 (0.53) | TACR1JAK2JAK1PDE4BUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389511-B2 | Bicyclic heterocyclic derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
| EP-2243779-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | REN, AGTR1, AGTR2 | TACR1 157/4885YAP1 595/4885JAK2 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.